EPL Archives
EPL Archives is recorded as a service provider in 15 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 15 of 15 trials · Latest update first
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1
Sponsor Alkermes Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
Sponsor Kardigan Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injury following cardiac surgery
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, placebo controlled, investigator and participant-blinded study, investigating safety, tolerability and efficacy of RHH646 in participants with knee osteoarthritis
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A 12-week randomized, participant and investigator blinded, placebo-controlled, exploratory study in adult participants with Chronic Urticaria to assess the efficacy and safety and explore the Mechanism of Action of remibrutinib (LOU064)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
Sponsor Otsuka Pharmaceutical Development And Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
Sponsor Alnylam Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People with Cystic Fibrosis
Sponsor Arcturus Therapeutics Europe B.V.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors
Sponsor IO Biotech ApS
- Start (EU)
- Latest update
- Estimated end
An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Long-term Follow-up Study of Patients with MPS IIIA from Gene Therapy Clinical Trials Involving the Administration of ABO-102 (scAAV9.U1a.hSGSH)
Sponsor Ultragenyx Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003‑P) in Participants with Tuberous Sclerosis Complex (1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) who Experience Inadequately‑controlled Seizures
Sponsor Gw Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
Sponsor Essa Pharma Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for EPL Archives?
The 2026-10-09 snapshot links EPL Archives to 15 distinct CTIS trials. Recorded services include Laboratory services, Long-term sample storage, Biobank, Long Term Storage, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for EPL Archives?
The most frequently recorded therapeutic areas are Cardiology, Neurology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to EPL Archives conducted?
The linked trials record locations in 21 countries, including Spain, France, Germany, Poland, Belgium. These are trial locations, not confirmed office locations or countries where EPL Archives delivered services.
What can this page tell me about EPL Archives's trial experience?
Browse 15 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 4 recorded name variants under EPL Archives. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- EPL Archives GmbH
- EPL Archives LLC
- EPL Archives, LLC
- Epl Archives